Navigation Links
Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
Date:6/1/2008

- Poster Presented at ASCO Annual Meeting -

SOUTH SAN FRANCISCO, Calif. and CHICAGO, June 1 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced safety and efficacy results from a previously unpublished Phase 1 clinical trial of picoplatin and liposomal doxorubicin in patients with advanced solid tumors, including ovarian cancer. Results demonstrated signals of clinical activity and acceptable toxicity with this combination.

Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent with the potential to address multiple indications, combinations and formulations. Doxorubicin, the active pharmaceutical ingredient of liposomal doxorubicin, is used in the treatment of a wide range of tumor types (e.g., breast, ovarian, lung, gastric, liver, bladder, thyroid, lymphomas and leukemias). Liposomal doxorubicin is approved for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. The standard of care for non-platinum-based chemotherapy in relapsed ovarian cancer is liposomal doxorubicin.

"The phase 1 trial in advanced solid tumors showed that both agents could be combined with an acceptable toxicity profile," said Don S. Dizon, M.D., assistant professor of obstetrics-gynecology and medicine at the Warren Alpert Medical School of Brown University. "In addition, the response rates observed with picoplatin with this new combination, particularly in those women with ovarian cancer, are promising and warrant further study. Advanced ovarian cancer is among the deadliest cancers, and patients who have failed initial therapy typically
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
2. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
3. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
4. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
5. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
6. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
7. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
8. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
11. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... BEDFORD, Mass. , Sept. 2, 2014  Hologic, Inc. (NASDAQ: ... , President and Chief Executive Officer, will present at the ... City , New York on ... Interested parties are invited to listen to the live ... Hologic,s website at www.hologic.com/investors-overview . An archive of the ...
(Date:9/2/2014)... 2, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... Drug Administration (FDA) has granted orphan drug status to ... "The FDA Office of Orphan Products Development ... to identify and designate drug candidates that could potentially ... development of such products," said Craig M. Audet ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 /PRNewswire/ ... announced the submission of a Marketing Authorization ... (EMA) via the centralized procedure for talimogene ... adults with melanoma that is regionally or ... immunotherapy administered as an intralesional injection that ...
Breaking Medicine Technology:Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6
... LAKES, N.J. , May 11 Nearly ... (LABAs) alone, and not in combination with other asthma ... and Drug Administration (FDA) on the risk of worsening ... according to a new study from the Medco ...
... May 11 Ethicon Endo-Surgery ... of surgical devices, the HARMONIC FOCUS® Long Curved Shears, ... that require deep access. The HARMONIC FOCUS® Long Curved ... using precise ultrasonic energy that minimizes thermal damage to ...
Cached Medicine Technology:Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 2Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 3Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 4Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 5Ethicon Endo-Surgery Introduces HARMONIC FOCUS(R) Long Curved Shears for Deep Surgical Access 2
(Date:9/2/2014)... (PRWEB) September 02, 2014 According ... http://www.idataresearch.com ), the leading global authority in medical ... market is expected to grow to over ... by an increase in the number of procedures ... kidney stones. This market includes TURP devices, laser ...
(Date:9/2/2014)... York (PRWEB) September 02, 2014 ... of nanotechnology in diagnosing, treating and/or prevention of ... applied for treating cardiovascular, neurological, and oncology diseases. ... of knowledge pertaining to various nanoparticles, their medical ... There still exists considerable scope for research in ...
(Date:9/2/2014)... Dallas, TX (PRWEB) September 02, 2014 On ... annual family health and fitness fair ¡Vive tu vida! Get ... and good nutrition for better health and wellness for people ... free and open to the public, will be held at ... from 8:00 am to 1:00 pm. , “Since 2007, ...
(Date:9/2/2014)... 2014 Durable Medical Goods manufacture ... leasing and financing company LeaseQ, Inc. to help customers ... Since late 2012, LeaseQ’s breakthrough finance shopping platform has ... they need to run their business. , Said ... enable the ThermoTek sales team to provide customers faster ...
(Date:9/2/2014)... 02, 2014 The American Healthcare Documentation ... Free-Tuition Guarantee for its ICD-10 Medical Coding Bridge Program. ... highest level of confidence to students who are seeking ... but are faced with the uncertainty brought on by ... ICD-10 until October 1st, 2015. , AHDPG’s Free-Tuition Guarantee ...
Breaking Medicine News(10 mins):Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Technology Manufacturer ThermoTek Announces New Partnership with LeaseQ.com to Help More Customers Acquire Equipment Faster and Cheaper 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 3
... January is Thyroid Awareness Month , JACKSONVILLE, Fla. , ... and feel our best. Yet many never realize that one of ... just below the neck.   , The thyroid is a small, ... affect the function of many of the body,s organs including the ...
... 2010 - Chronic and severely stressful situations, like those ... associated with smaller volumes in "stress sensitive" brain regions, ... and the hippocampus, a brain region involved in memory ... Biological Psychiatry , suggests that chronic insomnia may ...
... 27, 2010) Researchers at Tufts University School of Medicine ... have developed a new tool for gene therapy that significantly ... other carriers and DNA alone, according to a study published ... Medicine . The tool, a peptide called PEG-POD, provides a ...
... to delay lactation in new moms, researchers find , ... class of antidepressants can cause delayed lactation in new ... order to breast-feed their babies, a new study says. ... reuptake inhibitors (SSRIs), which include such drugs as Prozac ...
... ... ... recognition of cervical cancer awareness month, Debra Macki , one of the industry’s most ... of this preventable cancer. The palette includes three shades that represent the three tools women ...
... ... Payment Platform for Utah’s Answer to Health Care Reform , ... Salt Lake City, UT (Vocus) January 27, ... by the State of Utah to provide payment-processing solutions and HSA administration for the ...
Cached Medicine News:Health News:Unlocking the Secrets to a Healthier Body 2Health News:Unlocking the Secrets to a Healthier Body 3Health News:Losing sleep, losing brain? 2Health News:Researchers develop new tool for gene delivery 2Health News:Antidepressants May Complicate Breast-Feeding 2Health News:Celebrity Make-Up Artist Introduces New Eye Shadow Palette for Cervical Cancer Awareness 2Health News:Celebrity Make-Up Artist Introduces New Eye Shadow Palette for Cervical Cancer Awareness 3Health News:HealthEquity Partners with State of Utah to Launch Pilot of Utah Health Exchange 2Health News:HealthEquity Partners with State of Utah to Launch Pilot of Utah Health Exchange 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: